Ricks: Pharma must invest 20-25% of revenue in R&D for double-digit growth
Dave Ricks · Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma · Nov 11, 2025 · at 1:55:03
Eli Lilly CEO Dave Ricks explains Lilly's capital allocation philosophy and R&D reinvestment benchmarks to Patrick Collison.
0:00 / 0:11exact quote · 12.0s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“I have a belief that if you're not generating, to generate double digit growth in the sector, you need to invest at 20 to 25% of sales in R&D. That's sort of a good, a positive return R&D stack.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Dave Ricks
Ricks: PBM rebate incentives should be eliminated as unethical
“These PBMs and there's some group purchasing organizations like this. That should go away. And I think health is different than other commodities. It's probably has a much more important social role in deciding that the smallest, the little guy gets the worst …”
Ricks: Insurers initially refused to cover Eli Lilly's discounted generic insulin
“In the first year, no formularies covered this. So it was really only for that cash payer. No insurance company picked it up, even though it was dramatically cheaper. Now it's about half of the volume, but still half not because that model of this margin sprea…”
Ricks: Machine-designed drugs haven't reached clinical trials yet, but are coming
“I don't know of one that's come through the machine driven discovery process, which is really machine plus human that's made it to the clinic yet, but they're coming.”
Ricks: AI won't solve biology until we understand over 50% of it
“And today, I don't know, I would estimate we might know 10 to 15% of human biology. So the machine's not going to be good at all until we get way above 50%.”
Ricks: Claude and xAI beat ChatGPT for science because references check out
“I don't use that one for science actually. It's too, too horrible.
Patrick Collison: So which one do you use for science?
Dave Ricks: I tend to use either Claude or the XAI one. I find it more terse. And more, the references actually check out more often.”